Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has...